Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Plant Allergenic Extract [EPC]
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is a specialized biological agent classified as a non-standardized allergenic extract, primarily utilized in immunological diagnostics and targeted cytokine modulation research.
Name
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit
Raw Name
ANTI-INTERLEUKIN-1.ALPHA. IMMUNOGLOBULIN G RABBIT
Category
Non-Standardized Plant Allergenic Extract [EPC]
Drug Count
4
Variant Count
4
Last Verified
February 17, 2026
About Anti-interleukin-1.alpha. Immunoglobulin G Rabbit
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is a specialized biological agent classified as a non-standardized allergenic extract, primarily utilized in immunological diagnostics and targeted cytokine modulation research.
Detailed information about Anti-interleukin-1.alpha. Immunoglobulin G Rabbit
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Anti-interleukin-1.alpha. Immunoglobulin G Rabbit.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit represents a sophisticated biological product derived from the serum of rabbits (Oryctolagus cuniculus) that have been immunized against human interleukin-1 alpha (IL-1α). This agent is a polyclonal antibody, meaning it consists of a diverse mixture of immunoglobulin G (IgG) molecules that recognize various epitopes (binding sites) on the IL-1α protein. In the regulatory landscape of the United States Food and Drug Administration (FDA), this substance is categorized within the Established Pharmacologic Class (EPC) of Non-Standardized Plant Allergenic Extract [EPC], though it also carries designations related to standardized insect venoms and food extracts. This classification often stems from its historical use in diagnostic kits and specialized immunological testing where non-standardized biological reagents are utilized to assess immune reactivity.
Interleukin-1 alpha is a potent pro-inflammatory cytokine (a signaling protein) that plays a central role in the regulation of immune responses, inflammation, and hematopoiesis (blood cell production). Unlike its counterpart Interleukin-1 beta (IL-1β), which is secreted, IL-1α is often found in the cytosol or bound to the cell membrane, acting as an "alarmin" that triggers inflammatory cascades when cells are damaged. Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is designed to bind to this cytokine, neutralizing its biological activity and preventing it from interacting with the IL-1 receptor type I (IL-1RI).
The mechanism of action for Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is rooted in high-affinity antigen-antibody binding. As a polyclonal IgG, the rabbit-derived antibodies circulate and identify the human IL-1α molecule. Once binding occurs, the resulting immune complex prevents IL-1α from docking with its cognate receptor on the surface of target cells (such as macrophages, endothelial cells, and lymphocytes).
At the molecular level, the inhibition of IL-1α prevents the recruitment of the IL-1 receptor accessory protein (IL-1RAcP). Without this recruitment, the intracellular signaling domain (TIR domain) cannot initiate the phosphorylation cascade involving Interleukin-1 receptor-associated kinases (IRAKs) and the subsequent activation of Nuclear Factor-kappa B (NF-κB) and Mitogen-Activated Protein Kinases (MAPK). By quenching this signal, the drug effectively reduces the production of downstream inflammatory mediators, including prostaglandins, nitric oxide, and other chemokines. In diagnostic applications, the degree of binding or the inhibition of reactivity serves as a measurable marker for clinical assessment.
The pharmacokinetic behavior of rabbit-derived IgG in humans is distinct from humanized monoclonal antibodies due to the heterologous (foreign) nature of the protein.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is utilized in highly specific clinical and diagnostic scenarios. Its primary applications include:
This agent is typically available in the following formats:
> Important: Only your healthcare provider can determine if Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is right for your specific condition. The use of heterologous rabbit proteins carries significant risks that must be managed in a controlled clinical environment.
Dosage for Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is highly individualized and depends entirely on the intended application (diagnostic vs. therapeutic).
The safety and efficacy of Anti-interleukin-1.alpha. Immunoglobulin G Rabbit in pediatric populations have not been extensively established.
Formal dosage adjustments for renal impairment are generally not required for immunoglobulin products, as they are not cleared by the kidneys. However, patients with pre-existing renal disease should be monitored for secondary effects of protein load or potential immune-complex mediated glomerulonephritis (a rare complication of foreign protein administration).
No specific adjustments are documented for hepatic impairment. The metabolism of IgG occurs in the reticuloendothelial system rather than the liver's metabolic pathways.
Geriatric patients may have a higher baseline risk of adverse reactions due to age-related changes in immune function (immunosenescence). Dosing should be approached conservatively, starting at the lowest effective concentration for diagnostic purposes.
This medication is never self-administered. It must be given by a healthcare professional in a clinical setting equipped with emergency resuscitation equipment.
In the context of diagnostic testing, a missed dose simply requires rescheduling the appointment. For patients receiving a series of injections, the healthcare provider will determine the appropriate interval to restart or continue the series. Do not double the dose to "catch up."
An overdose of Anti-interleukin-1.alpha. Immunoglobulin G Rabbit increases the risk of systemic allergic reactions and serum sickness.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or attempt to administer this product without professional medical guidance.
Most side effects associated with Anti-interleukin-1.alpha. Immunoglobulin G Rabbit are localized to the site of administration, especially when used for diagnostic purposes.
> Warning: Stop taking Anti-interleukin-1.alpha. Immunoglobulin G Rabbit and call your doctor immediately if you experience any of these symptoms of a severe reaction.
Because Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is typically used for short-term diagnostic purposes, long-term side effects are rare. However, repeated exposure can lead to:
While specific "Black Box" warnings are often reserved for standardized pharmaceutical drugs, the class of allergenic extracts carries a general FDA-mandated warning regarding Anaphylaxis.
Summary of Warning: This product can cause severe, life-threatening systemic allergic reactions, including anaphylaxis. It should only be administered by physicians who are exceptionally experienced in the treatment of systemic reactions and in facilities where equipment for resuscitation is immediately available. Patients must be observed for an extended period following administration. Patients with unstable asthma or those taking beta-blockers may be at increased risk for severe outcomes if a reaction occurs.
Report any unusual symptoms to your healthcare provider immediately. Even a mild rash can be a precursor to a more serious systemic event.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is a biological product that introduces foreign animal protein into the human body. This inherently carries a risk of immunological sensitization. Patients must be screened for any history of allergies to animals, specifically rabbits, before administration. It is also vital to understand that this agent modulates the interleukin-1 pathway, which is a key component of the innate immune system's defense against pathogens.
No specific FDA black box warnings are currently listed for "Anti-interleukin-1.alpha. Immunoglobulin G Rabbit" as a standalone entity, but it falls under the general warnings for Allergenic Extracts. These warnings emphasize the risk of severe systemic reactions and the requirement for administration in a controlled medical setting. The primary concern is the potential for rapid-onset anaphylaxis, which can occur even in patients who have previously tolerated the product without issue.
There is no evidence that Anti-interleukin-1.alpha. Immunoglobulin G Rabbit directly impairs the ability to drive or operate machinery. However, if a patient experiences dizziness, lightheadedness, or a vasovagal response following the injection, they should avoid these activities until symptoms completely resolve.
While there is no direct chemical interaction between alcohol and rabbit IgG, alcohol consumption can cause vasodilation and may potentially exacerbate an allergic reaction or make it more difficult to treat. It is generally advised to avoid alcohol for 24 hours following administration.
For diagnostic use, discontinuation is not applicable as it is often a single-use event. If used in a series, the healthcare provider may decide to discontinue the product if the patient develops high levels of anti-rabbit antibodies or experiences a systemic reaction.
> Important: Discuss all your medical conditions, especially any history of asthma or previous reactions to animal-derived products, with your healthcare provider before starting Anti-interleukin-1.alpha. Immunoglobulin G Rabbit.
There are no known direct food interactions with Anti-interleukin-1.alpha. Immunoglobulin G Rabbit. However, if the patient has a known food allergy that is being tested simultaneously, the results must be interpreted carefully to avoid cross-reactivity issues.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially those that affect your immune system or your skin's sensitivity.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit must NEVER be used in the following circumstances:
Conditions requiring a careful risk-benefit analysis include:
There is a potential for cross-sensitivity with other lagomorph-derived products. Additionally, patients who are highly sensitive to other mammalian proteins (such as bovine or equine globulins) should be approached with caution, although the specific epitopes are usually different.
> Important: Your healthcare provider will evaluate your complete medical history, including all past allergic reactions, before prescribing or administering Anti-interleukin-1.alpha. Immunoglobulin G Rabbit.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is generally classified in a category equivalent to FDA Category C. This means that animal reproduction studies have not been conducted with this specific agent, and it is not known whether it can cause fetal harm when administered to a pregnant woman.
It is not known whether Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is excreted in human milk. However, since human IgG is naturally present in breast milk, it is highly probable that rabbit IgG would also be excreted.
As noted previously, the use of this agent in children is limited. Pediatric patients have a more reactive immune system, which can lead to more pronounced wheal and flare reactions in diagnostic testing.
Clinical studies of Anti-interleukin-1.alpha. Immunoglobulin G Rabbit did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.
No dosage adjustment is typically required for patients with renal impairment. However, in cases of severe renal failure, the clearance of immune complexes might be altered. These patients should be monitored for signs of proteinuria or worsening renal function following administration.
There are no specific guidelines for use in hepatic impairment. Because the liver is not the primary site of clearance for IgG, the pharmacokinetics are unlikely to be significantly altered. However, patients with cirrhosis may have altered immune responses and should be monitored closely.
> Important: Special populations require individualized medical assessment and a higher level of clinical monitoring during and after the administration of biological products.
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit functions as a competitive antagonist of human Interleukin-1 alpha. By binding to the IL-1α protein with high specificity, the antibody masks the site that normally interacts with the IL-1 Receptor Type I (IL-1RI).
IL-1α is unique because it possesses a nuclear localization sequence and can act as a transcription factor, in addition to its role as a cell-surface and secreted cytokine. The rabbit IgG primarily targets the extracellular and membrane-bound forms. By preventing the formation of the IL-1α/IL-1RI/IL-1RAcP signaling complex, the drug halts the activation of the MyD88-dependent pathway. This prevents the translocation of NF-κB to the nucleus, thereby inhibiting the transcription of pro-inflammatory genes.
The pharmacodynamic effect of the drug is the reduction of IL-1-mediated inflammation.
| Parameter | Value |
|---|---|
| Bioavailability | ~60-80% (Subcutaneous) |
| Protein Binding | N/A (It is a protein) |
| Half-life | 5 - 10 days (in humans) |
| Tmax | 48 - 72 hours |
| Metabolism | Proteolysis (Reticuloendothelial System) |
| Excretion | Minimal Renal; mostly cellular degradation |
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit belongs to the class of Allergenic Extracts and more specifically the sub-class of Cytokine Antagonists (Heterologous). It is related to other anti-IL-1 therapies like Anakinra (recombinant IL-1 receptor antagonist) and Canakinumab (human monoclonal anti-IL-1β), but it is distinct due to its rabbit origin and its specific targeting of the alpha isoform.
Medications containing this ingredient
Common questions about Anti-interleukin-1.alpha. Immunoglobulin G Rabbit
Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is primarily used as a diagnostic tool in immunology to assess a patient's sensitivity to interleukin-1 alpha, a key inflammatory protein. It is often part of specialized skin testing or laboratory assays to help doctors understand complex autoinflammatory conditions. In some research settings, it may be used to study the effects of neutralizing specific cytokines in the body. It is not a standard first-line treatment for common ailments but a specialized biological reagent. Always consult your immunologist to understand why this specific test or agent is being used in your care.
The most frequent side effects are localized to the site where the drug is injected, including redness, swelling, itching, and a small hard bump (induration). These symptoms are usually mild and disappear within a day or two as the body processes the protein. Some patients may also experience a mild headache or a low-grade fever shortly after administration. Because it is a foreign protein from a rabbit, the immune system naturally reacts to it. If you notice a rash spreading across your body or have trouble breathing, you must seek emergency medical help immediately.
It is generally recommended to avoid alcohol for at least 24 hours after receiving an injection of Anti-interleukin-1.alpha. Immunoglobulin G Rabbit. Alcohol can cause your blood vessels to dilate, which might worsen any localized swelling or redness at the injection site. More importantly, alcohol can sometimes mask or mimic the early symptoms of an allergic reaction, making it harder for you or your doctor to identify a serious problem. To ensure the most accurate diagnostic results and for your safety, stay hydrated with water instead. Always follow the specific post-procedure instructions provided by your healthcare facility.
The safety of this agent during pregnancy has not been established through rigorous clinical trials. Since it is a rabbit-derived antibody, there is a possibility that it could cross the placenta and affect the developing immune system of the fetus. Doctors typically avoid using this product in pregnant women unless the diagnostic information it provides is essential for the mother's health and cannot be obtained another way. If you are pregnant or planning to become pregnant, you must inform your doctor before any immunological testing. A thorough risk-benefit analysis is required for every individual case.
In the context of a diagnostic skin test, the results are usually visible within 15 to 30 minutes after the injection. This is known as the "immediate hypersensitivity" phase, where the doctor looks for a wheal (a raised bump) and flare (redness). If the agent is being used for its systemic neutralizing effects in a research setting, it may take 24 to 72 hours to reach peak levels in the bloodstream. The anti-inflammatory effects would then develop gradually over the following days. Your healthcare provider will monitor you closely during this entire period to evaluate the response.
Since Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is usually administered as a single diagnostic dose or a short series of injections by a professional, "stopping" it like a daily pill isn't typical. However, if you are undergoing a series of treatments and decide to stop, there is no risk of a traditional withdrawal syndrome. The main concern with stopping or skipping doses is that the diagnostic information may be incomplete, or your immune system might develop a stronger reaction if the series is restarted later. Always discuss your concerns with your doctor before deciding to discontinue any medical procedure.
If you miss an appointment for an injection of Anti-interleukin-1.alpha. Immunoglobulin G Rabbit, contact your healthcare provider's office as soon as possible to reschedule. Missing a dose in a diagnostic sequence can make the results harder to interpret. You do not need to take any special actions at home, as this medication is only handled by professionals. Your doctor will determine if the testing needs to be restarted from the beginning or if it can simply continue. Consistency is key to getting accurate results from immunological tests.
There is no clinical evidence to suggest that Anti-interleukin-1.alpha. Immunoglobulin G Rabbit causes weight gain. Unlike long-term corticosteroid therapy, which is known to affect metabolism and fat distribution, this biological agent works specifically on the interleukin-1 alpha pathway and is typically used for short durations. Any sudden weight changes while undergoing immunological testing should be reported to your doctor, as they might be related to an underlying condition or a different medication. Your healthcare team can help you determine the cause of any unexpected physical changes.
This agent can interact with several types of medications, particularly those that affect the immune system. For example, antihistamines and steroids can dampen the skin's reaction, leading to inaccurate diagnostic results. Other biologics that suppress the immune system can increase your risk of infection if used at the same time. It is vital that you provide your doctor with a complete list of all prescriptions, over-the-counter drugs, and herbal supplements you are taking. This allows them to safely coordinate your care and ensure that the Anti-interleukin-1.alpha. Immunoglobulin G Rabbit works as intended.
No, Anti-interleukin-1.alpha. Immunoglobulin G Rabbit is a complex biological product and is not available in a generic form. Biological products are grown in living systems (in this case, rabbits), which makes them much more difficult to replicate than standard chemical drugs. While there may be different brands or versions of rabbit-derived antibodies, they are not considered interchangeable generics. The specific product used by your doctor is chosen based on its purity, concentration, and the specific diagnostic standards required for your test.